report revenu consist earli
januari pre-announce ebit margin solid prudent
expens manag off-set lighter gross margin overal littl
surpris accompani print better result everi geographi
underscor grow adopt impella also posit
roll-out impella connect expect drive better outcom
creat ancillari revenu line think stock feel share
continu work continu quarterli beat especi
japan contribut new geographi long market
remain bullish would also endors invest posit ahead
posit analyst day updat later commenc
stemi dtu trial combin under-penetr core
market robust gross margin expans new geographi roll-
multipl next-gener product posit well
support case share out-performance remain buyer
reiter pt
servic admittedli werent mani new updat sinc
highlight today includ plan analyst day late
updat market estim provid roll-out
impella connect select hospit latter develop management
discuss provid real-tim cloud-bas support past
today provid exampl crystal valu real-
time remot call center assist hospit clinician time
see multipl way win improv outcom mine data fine-
tune algorithm best practic new revenu line
tweak model increas revenu estim
upsid improv outlook japan
valuat reiter buy rate pt risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
compani report world-wide impella revenu in-lin
pre-announc earli januari impella revenu
grow better product mix pad util growth ou
impella revenu improv y/i revenu japan
last quarter manag anticip full year japan
contribut total initi forecast
quarter site open japan bring total reach hospit
manag estim impella still penetr countri
amp relat spend roll increment impella product
gross margin weaker forecast pressur
attribut manufactur invest direct labor cost sale
mix sg spend slightli less model despit higher
market stock compens expens lastli in-lin
compani continu funnel expens toward new product
develop ecp well on-going data collect cvad registri
overal ebit margin better model ep
includ excess tax benefit relat stock-bas
actualsbtig estimate varianceu impella sale trial impella sale revenu growth net incom bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
make minor tweak revenu forecast essenti flow
beat although impella traction particularli ou
continu encourag prefer conserv
forecast light tough comparison margin trim
gross margin forecast bit reflect weak balanc
ebit margin move fairli unchang prior estim
rate buy pt base month
revenu estim similar current multipl share trade
feel compani above-averag revenu growth gross margin warrant
premium multipl peer importantli feel multipl
driver potenti upsid street estim includ label expans
stemi popul sizabl treatment pool previous
estim via use diseas area like renal failur acut kidney
injuri geograph reach market risk rate price
target includ reimburs slippag product timelin chang
procedur patent litig data fda
exhibit comp tabl fast-grow med-tech compani
impella sale impella sale net incom btig estim compani model tax benefit go-forward basi estim may directli compar consensu forecast newold changentm inc ingnnot factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella y/i inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
